Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia (Q42683637)

4 November 2017

title

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia (English)

1 reference

4 November 2017

0 references

1 reference

Guyton JR

1

1 reference

4 November 2017

Goldberg AC

2

1 reference

4 November 2017

Kreisberg RA

3

1 reference

4 November 2017

Sprecher DL

4

1 reference

4 November 2017

Superko HR

5

1 reference

4 November 2017

O'Connor CM

6

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

American Journal of Cardiology

4 November 2017

published in

1 reference

4 November 2017

volume

82

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

737-743

1 reference

Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Hepatic toxicity of unmodified and time-release preparations of niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Lovastatin, nicotinic acid, and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Niacin revisited: clinical observations on an important but underutilized drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Fluvastatin with and without niacin for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

Familial lipoprotein disorders and premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900448-2

10.1016/S0002-9149(98)00448-2

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference